List of Excipients in API insulin glargine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing insulin glargine
Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
---|---|---|---|---|---|
A-S Medication Solutions | LANTUS | insulin glargine | 50090-0876 | GLYCERIN | |
A-S Medication Solutions | LANTUS | insulin glargine | 50090-0876 | HYDROCHLORIC ACID | |
A-S Medication Solutions | LANTUS | insulin glargine | 50090-0876 | METACRESOL | |
A-S Medication Solutions | LANTUS | insulin glargine | 50090-0876 | POLYSORBATE 20 | |
>Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for insulin glargine
Excipient focus: GLYCERIN
insulin glargine drug variants containing GLYCERIN
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing GLYCERIN
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
insulin glargine drug variants containing HYDROCHLORIC ACID
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
Winthrop US | insulin glargine | 0955-1729 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing HYDROCHLORIC ACID
Company | Ingredient | NDC |
---|---|---|
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
A-S Medication Solutions | insulin glargine | 50090-2193 |
A-S Medication Solutions | insulin glargine | 50090-4177 |
>Company | >Ingredient | >NDC |
Excipient focus: METACRESOL
insulin glargine drug variants containing METACRESOL
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing METACRESOL
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: METHIONINE
insulin glargine drug variants containing METHIONINE
Company | Ingredient | NDC |
---|---|---|
sanofi-aventis US LLC | insulin glargine and lixisenatide | 0024-5761 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing METHIONINE
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
>Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
insulin glargine drug variants containing POLYSORBATE 20
Company | Ingredient | NDC |
---|---|---|
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
Winthrop US | insulin glargine | 0955-1729 |
Sanofi-Aventis Deutschland GmbH | insulin glargine | 12854-433 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing POLYSORBATE 20
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
Winthrop US a business of sanofi-aventis US LLC | insulin glargine | 0955-3900 |
Mylan Specialty LP | insulin glargine | 49502-196 |
>Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
insulin glargine drug variants containing SODIUM HYDROXIDE
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
Winthrop US | insulin glargine | 0955-1729 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing SODIUM HYDROXIDE
Company | Ingredient | NDC |
---|---|---|
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
A-S Medication Solutions | insulin glargine | 50090-2193 |
A-S Medication Solutions | insulin glargine | 50090-4177 |
>Company | >Ingredient | >NDC |
Excipient focus: WATER
insulin glargine drug variants containing WATER
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing WATER
Company | Ingredient | NDC |
---|---|---|
>Company | >Ingredient | >NDC |
Excipient focus: ZINC
insulin glargine drug variants containing ZINC
Company | Ingredient | NDC |
---|---|---|
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
Winthrop US | insulin glargine | 0955-1729 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing ZINC
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
sanofi-aventis US LLC | insulin glargine and lixisenatide | 0024-5761 |
Mylan Specialty LP | insulin glargine-yfgn | 49502-251 |
Mylan Specialty LP | insulin glargine-yfgn | 49502-394 |
>Company | >Ingredient | >NDC |
Excipient focus: ZINC CHLORIDE
insulin glargine drug variants containing ZINC CHLORIDE
Company | Ingredient | NDC |
---|---|---|
sanofi-aventis US LLC | insulin glargine and lixisenatide | 0024-5761 |
Mylan Specialty LP | insulin glargine-yfgn | 49502-251 |
Mylan Specialty LP | insulin glargine-yfgn | 49502-394 |
Biocon Biologics Inc | insulin glargine-yfgn | 83257-012 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing ZINC CHLORIDE
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
>Company | >Ingredient | >NDC |
Excipient focus: ZINC OXIDE
insulin glargine drug variants containing ZINC OXIDE
Company | Ingredient | NDC |
---|---|---|
Eli Lilly and Company | insulin glargine | 0002-7715 |
>Company | >Ingredient | >NDC |
insulin glargine drug variants not containing ZINC OXIDE
Company | Ingredient | NDC |
---|---|---|
Sanofi-Aventis US LLC | insulin glargine | 0024-5869 |
sanofi-aventis US LLC | insulin glargine | 0088-2220 |
sanofi-aventis US LLC | insulin glargine | 0088-5021 |
Winthrop US | insulin glargine | 0955-1729 |
>Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.